

Saurabh Zanwar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/35850/saurabh-zanwar-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

358
citations

11
h-index

17
g-index

61
ext. papers

500
ext. citations

3.4
avg, IF

3.44
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 53 | Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536 | 10.7 | 60 |
| 52 | Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1403-1411 | 2.2 | 36 |
| 51 | mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. <i>OncoTargets and Therapy</i> , 2017 , 10, 1859-1863 | 4.4 | 30 |
| 50 | Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403 | 4.5 | 23 |
| 49 | Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281 | 7.1 | 18 |
| 48 | Immune-based therapies in the management of multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 84 | 7 | 18 |
| 47 | Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794 | 10.7 | 16 |
| 46 | Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393 | 7.1 | 15 |
| 45 | Ixazomib: a novel drug for multiple myeloma. <i>Expert Review of Hematology</i> , 2018 , 11, 761-771 | 2.8 | 13 |
| 44 | Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). <i>International Journal of Surgical Oncology</i> , 2016 , 2016, 6923730 | 0.9 | 12 |
| 43 | Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. <i>Transplant Infectious Disease</i> , 2019 , 21, e13017 | 2.7 | 12 |
| 42 | Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 958-967 | 2.8 | 10 |
| 41 | Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019 , 14, 70-82 | 4.4 | 10 |
| 40 | Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India. <i>Indian Journal of Cancer</i> , 2016 , 53, 313-316 | 0.9 | 8 |
| 39 | Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. <i>South Asian Journal of Cancer</i> , 2016 , 5, 182-185 | 0.7 | 7 |
| 38 | Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients. <i>Indian Journal of Cancer</i> , 2017 , 54, 280-284 | 0.9 | 7 |
| 37 | Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7559-7559 | 2.2 | 6 |

| | | | |
|----|--|------|---|
| 36 | Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 31-43 | 4.4 | 5 |
| 35 | Rectal GIST-Outcomes and viewpoint from a tertiary cancer center. <i>Indian Journal of Gastroenterology</i> , 2016 , 35, 445-449 | 1.9 | 5 |
| 34 | Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. <i>Annals of Translational Medicine</i> , 2016 , 4, 74 | 3.2 | 5 |
| 33 | Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216 | 4.5 | 5 |
| 32 | Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7509-7509 | 2.2 | 4 |
| 31 | A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021 , 106, 2940-2946 | 6.6 | 4 |
| 30 | Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. <i>Indian Journal of Cancer</i> , 2017 , 54, 678-680 | 0.9 | 4 |
| 29 | Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 45-55 | 4.4 | 3 |
| 28 | A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2017 , 48, 100-102 | 1.6 | 3 |
| 27 | Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021 , 192, 542-550 | 4.5 | 3 |
| 26 | Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. <i>Indian Journal of Medical Research</i> , 2018 , 148, 284-290 | 2.9 | 2 |
| 25 | Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953 | 7.1 | 2 |
| 24 | Impact of Surveillance Stool Culture Guided Selection of Antibiotics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2016 , 128, 3389-3389 | 2.2 | 1 |
| 23 | Efficacy of Cobimetinib in Rosai-Dorfman Disease. <i>Blood</i> , 2021 , 138, 1506-1506 | 2.2 | 1 |
| 22 | BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics. <i>Blood</i> , 2021 , 138, 2582-2582 | 2.2 | 1 |
| 21 | Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. <i>Indian Journal of Cancer</i> , 2016 , 53, 579-582 | 0.9 | 1 |
| 20 | Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 , | 10.7 | 1 |
| 19 | Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018 , 132, 1606-1606 | 2.2 | 1 |

| | | | |
|----|---|-----|---|
| 18 | Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884 | 2.2 | 1 |
| 17 | Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018 , 132, 4152-4152 | | 1 |
| 16 | Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20628-e20628 | 2.2 | 1 |
| 15 | Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979 | 1.9 | 1 |
| 14 | The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158 | 7 | 1 |
| 13 | Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221093962 | 5.7 | 1 |
| 12 | Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3087-3097 | 1.9 | 0 |
| 11 | Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2599-2601 | 1.9 | |
| 10 | The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020 , 136, 39-40 | 2.2 | |
| 9 | Waldenström Macroglobulinemia in the Very Elderly (≥ 85 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45 | 2.2 | |
| 8 | High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. <i>Blood</i> , 2021 , 138, 2526-2526 | 2.2 | |
| 7 | Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632 | 2.2 | |
| 6 | Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1439-1439 | 2.2 | |
| 5 | Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1912-1912 | 2.2 | |
| 4 | Current Therapeutic Options in Waldenström Macroglobulinemia. <i>Oncology & Hematology Review</i> , 2019 , 15, 39 | 0.1 | |
| 3 | Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019 , 134, 1532-1532 | | |
| 2 | Use of Antibiotic Lock for Salvage of Tunneled Central Venous Catheters with Catheter Colonisation and Catheter Related Blood Stream Infection in a Tertiary Care Hematopoietic Stem Cell Transplantation Unit- a Strategy Revisited. <i>Blood</i> , 2015 , 126, 3116-3116 | 2.2 | |
| 1 | 66-Year-Old Man With Recurrent Hypotension and Flank Pain. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1622-1622 | | |

